aTyr Pharma of San Diego and Hong Kong Plans $86 Million IPO

aTyr Pharma, a San Diego-Hong Kong clinical stage biotherapeutics company, filed to conduct an $86 million IPO on the NASDAQ exchange. The company develops Physiocrine-based therapeutics to address rare diseases. Its lead molecule, Resolaris, is currently in a Phase Ib/II trial in adult patients with facioscapulohumeral muscular dystrophy. Founded in 2005 by Paul Schimmel, PhD and Xiang-Lei Yang, PhD, the company has a Hong Kong subsidiary, Pangu BioPharma, which operates a laboratory at the Hong Kong University of Science and Technology. More details.... Share this with colleagues: // //